|
1
|
Anderson JL, Adams CD, Antman EM, Bridges
CR, Califf RM, Casey DE Jr, Chavey WE II, Fesmire FM, Hochman JS,
Levin TN, et al: 2012 ACCF/AHA focused update incorporated into the
ACCF/AHA 2007 guidelines for the management of patients with
unstable angina/non-ST-elevation myocardial infarction: A report of
the American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines. J Am Coll Cardiol.
61:e179–e347. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Go AS, Mozaffarian D, Roger VL, Benjamin
EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, et al:
American Heart Association Statistica Committee and Stroke
Statistics Subcommittee: Heart disease and stroke statistics-2013
update: A report from the American Heart Association. Circulation.
127:e6–e245. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chase M, Robey JL, Zogby KE, Sease KL,
Shofer FS and Hollander JE: Prospective validation of the
Thrombolysis in Myocardial Infarction Risk Score in the emergency
department chest pain population. Ann Emerg Med. 48:252–259. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lyon R, Morris AC, Caesar D, Gray S and
Gray A: Chest pain presenting to the Emergency Department - to
stratify risk with GRACE or TIMI? Resuscitation. 74:90–93. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hess EP, Perry JJ, Calder LA,
Thiruganasambandamoorthy V, Body R, Jaffe A, Wells GA and Stiell
IG: Prospective validation of a modified thrombolysis in myocardial
infarction risk score in emergency department patients with chest
pain and possible acute coronary syndrome. Acad Emerg Med.
17:368–375. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee B, Chang AM, Matsuura AC, Marcoon S
and Hollander JE: Comparison of cardiac risk scores in ED patients
with potential acute coronary syndrome. Crit Pathw Cardiol.
10:64–68. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Karlberg KE, Saldeen T, Wallin R,
Henriksson P, Nyguist O and Sylvén C: Intravenous nitroglycerin
reduces ischaemia in unstable angina pectoris: A double-blind
placebo-controlled study. J Intern Med. 243:25–31. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kontos MC, Diercks DB, Ho PM, Wang TY,
Chen AY and Roe MT: Treatment and outcomes in patients with
myocardial infarction treated with acute beta-blocker therapy:
Results from the American College of Cardiology's NCDR(®). Am Heart
J. 161:864–870. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moss AJ, Oakes D, Rubison M, McDermott M,
Carleen E, Eberly S and Browm M: Effects of diltiazem on long-term
outcome after acute myocardial infarction in patients with and
without a history of systemic hypertension. The Multicenter
Diltiazem Postinfarction Trial Research Group. Am J Cardiol.
68:429–433. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yusuf S, Sleight P, Pogue J, Bosch J,
Davies R and Dagenais G: Effects of an
angiotensin-converting-enzyme inhibitor, ramipril, on
cardiovascular events in high-risk patients. The Heart Outcomes
Prevention Evaluation Study Investigators. N Engl J Med.
342:145–153. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cannon CP, Braunwald E, McCabe CH, Rader
DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA and Skene
AM: Pravastatin or Atorvastatin Evaluation and Infection
Therapy-Thrombolysis in Myocardial Infarction 22 Investigators:
Intensive versus moderate lipid lowering with statins after acute
coronary syndromes. N Engl J Med. 350:1495–1504. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cohen M, Demers C, Gurfinkel EP, Turpie
AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur
J and Bigonzi F: A comparison of low-molecular-weight heparin with
unfractionated heparin for unstable coronary artery disease.
Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave
Coronary Events Study Group. N Engl J Med. 337:447–452. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yusuf S, Zhao F, Mehta SR, Chrolavicius S,
Tognoni G and Fox KK: Clopidogrel in Unstable Angina to Prevent
Recurrent Events Trial Investigators: Effects of clopidogrel in
addition to aspirin in patients with acute coronary syndromes
without ST-segment elevation. N Engl J Med. 345:494–502. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
James SK, Roe MT, Cannon CP, Cornel JH,
Horrow J, Husted S, Katus H, Morais J, Steg PG, Storey RF, et al:
PLATO Study Group: Ticagrelor versus clopidogrel in patients with
acute coronary syndromes intended for non-invasive management:
substudy from prospective randomised PLATelet inhibition and
patient Outcomes (PLATO) trial. BMJ. 342:d35272011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Anderson SD, Shah NK, Yim J and Epstein
BJ: Efficacy and safety of ticagrelor: a reversible P2Y12 receptor
antagonist. Ann Pharmacother. 44:524–537. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kushner FG, Hand M, Smith SC Jr, King SB
III, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC,
Casey DE Jr, et al: 2009 focused updates: ACC/AHA guidelines for
the management of patients with ST-elevation myocardial infarction
(updating the 2004 guideline and 2007 focused update) and
ACC/AHA/SCAI guidelines on percutaneous coronary intervention
(updating the 2005 guideline and 2007 focused update) a report of
the American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines. J Am Coll Cardiol.
54:2205–2241. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vlachojannis GJ, Dimitropoulos G and
Alexopoulos D: Clopidogrel resistance: Current aspects and future
directions. Hellenic J Cardiol. 52:236–245. 2011.PubMed/NCBI
|
|
18
|
Sofi F, Marcucci R, Gori AM, Giusti B,
Abbate R and Gensini GF: Clopidogrel non-responsiveness and risk of
cardiovascular morbidity. An updated meta-analysis. Thromb Haemost.
103:841–848. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
AstraZeneca: Cardiobascular and metabolic
diseases. http://www.astrazeneca.com/medicines/cardiovascular/product/brilinta-briliqueAccessed.
January 10–2013
|
|
20
|
Wallentin L, Becker RC, Budaj A, Cannon
CP, Emanuelsson H, Held C, Horrow J, Husted S, James S and Katus H:
PLATO Investigators, et al: Ticagrelor versus clopidogrel in
patients with acute coronary syndromes. N Engl J Med.
361:1045–1057. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Eagle KA, Guyton RA, Davidoff R, Ewy GA,
Fonger J, Gardner TJ, Gott JP, Herrmann HC, Marlow RA, Nugent WC,
et al: 1999 ACC/AHA Guidelines for Coronary Artery Bypass Graft
Surgery: A Report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines. J Am Coll
Cardiol. 34:1262–1347. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dolgin M: Nomenclature and Criteria for
Diagnosis of Diseases of the Heart and Great Vessels (9th).
Philadelphia, PA: Lippincott Williams and Wilkins. 253–256.
1994.
|
|
23
|
The TIMI Study Group. The Thrombolysis in
Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med.
312:932–936. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Levine GN, Bates ER, Blankenship JC,
Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA,
Hollenberg SM, et al: American College of Cardiology Foundation;
American Heart Association Task Force on Practice Guidelines;
Society for Cardiovascular Angiography and Interventions: 2011
ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A
report of the American College of Cardiology Foundation/American
Heart Association Task Force on Practice Guidelines and the Society
for Cardiovascular Angiography and Interventions. J Am Coll
Cardiol. 58:e44–e122. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gurbel PA, Antonino MJ and Tantry US:
Recent developments in clopidogrel pharmacology and their relation
to clinical outcomes. Expert Opin Drug Metab Toxicol. 5:989–1004.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
James S, Akerblom A, Cannon CP,
Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF,
Harrington R, et al: Comparison of ticagrelor, the first reversible
oral P2Y (12) receptor antagonist, with clopidogrel in patients
with acute coronary syndromes: Rationale, design, and baseline
characteristics of the PLATelet inhibition and patient Outcomes
(PLATO) trial. Am Heart J. 157:599–605. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Storey RF, Husted S, Harrington RA,
Heptinstall S, Wilcox RG, Peters G, Wickens M, Emanuelsson H,
Gurbel P, Grande P and Cannon CP: Inhibition of platelet
aggregation by AZD6140, a reversible oral P2Y12 receptor
antagonist, compared with clopidogrel in patients with acute
coronary syndromes. J Am Coll Cardiol. 50:1852–1856. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Husted S, Emanuelsson H, Heptinstall S,
Sandset PM, Wickens M and Peters G: Pharmacodynamics,
pharmacokinetics, and safety of the oral reversible P2Y12
antagonist AZD6140 with aspirin in patients with atherosclerosis: A
double-blind comparison to clopidogrel with aspirin. Eur Heart J.
27:1038–1047. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Storey RF, Angiolillo DJ, Patil SB, Desai
B, Ecob R, Husted S, Emanuelsson H, Cannon CP, Becker RC and
Wallentin L: Inhibitory effects of ticagrelor compared with
clopidogrel on platelet function in patients with acute coronary
syndromes: The PLATO (Platelet inhibition and patient outcomes)
PLATELET substudy. J Am Coll Cardiol. 56:1456–1462. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tantry US, Bliden KP and Gurbel PA:
Resistance to antiplatelet drugs: Current status and future
research. Expert Opin Pharmacother. 6:2027–2045. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gurbel PA, Bliden KP, Hayes KM and Tantry
U: Platelet activation in myocardial ischemic syndromes. Expert Rev
Cardiovasc Ther. 2:535–545. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gurbel PA, Bliden KP, Zaman KA, Yoho JA,
Hayes KM and Tantry US: Clopidogrel loading with eptifibatide to
arrest the reactivity of platelets: Results of the clopidogrel
loading with eptifibatide to arrest the reactivity of platelets
(CLEAR PLATELETS) study. Circulation. 111:1153–1159. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gurbel PA, Bliden KP, Samara W, Yoho JA,
Hayes K, Fissha MZ and Tantry US: Clopidogrel effect on platelet
reactivity in patients with stent thrombosis: Results of the CREST
study. J Am Coll Cardiol. 46:1827–1832. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang K, Zhou X, Huang Y, Khalil M, Wiktor
D, van Giezen JJ and Penn MS: Adjunctive treatment with ticagrelor,
but not clopidogrel, added to tPA enables sustained coronary artery
recanalisation with recovery of myocardium perfusion in a canine
coronary thrombosis model. Thromb Haemost. 104:609–617. 2010.
View Article : Google Scholar : PubMed/NCBI
|
